The British specialty pharma company BTG Plc has broadened its portfolio of treatments for hospital procedures with the acquisition of Roxwood Medical Inc of Redwood City, California. The deal is valued at up to $80 million.
Three European-born scientists have been awarded the 2017 Nobel Prize in Chemistry for their development of cryo-electron microscopy, which is a technique for simplifying and improving the images of biomolecules. The award was announced on 4 October.
Ablynx NV has filed registration documents with the US Securities and Exchange Commission to raise up to $150 million in an initial public offering of its shares on Nasdaq. Based in Ghent, Belgium, Ablynx went public on Euronext in Brussels in 2007.
Novartis has announced a new academic alliance to explore the proteome as a source of new drug leads for cancer and other serious diseases. The collaboration is with the University of California Berkeley, US.
Evotec AG has made a €15 million equity investment in Exscientia Ltd which is developing artificial intelligence technologies to aid drug discovery. The German company already has a research collaboration with Exscientia dating from 2016.
UK-based Autolus Ltd has secured $80 million in Series C capital from new and existing investors to advance the development of its engineered T cell therapies for cancer. The new investors include US-based Cormorant Asset Management and Nextech Invest of Switzerland.
It is one thing to research and develop an advanced therapy medicinal product (ATMP), but quite another to bring it successfully to market. Among the nine ATMPs approved in Europe since 2009, only five are still on the market.
The Bill & Melinda Gates Foundation is to invest up to $40 million in Immunocore Ltd to support the development of the company’s T cell receptor technology (TCR) for infectious disease. The UK company already has partnerships exploring TCRs against cancer.
New longer-term data from a Phase 3 trial of the drug guselkumab for plaque psoriasis has shown that patients achieved consistent rates of skin clearance following treatment at both 52 and 100 weeks, according to the developer Janssen Research & Development LLC.
The European Medicines Agency has recommended two new cancer drugs for approval in Europe, each with an entirely different mechanisms of action. The first is a PARP inhibitor for ovarian cancer and the second, a photodynamic therapy for prostate cancer.